C3.ai Inc vs Heron Therapeutics Inc — how do they compare? C3.ai Inc trades at $10.6 (market cap $1.59B), while Heron Therapeutics Inc trades at $0.32 (market cap $63.41M). The key difference: C3.ai Inc is far larger — about 25.1× Heron Therapeutics Inc's market cap, and C3.ai Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| AI | HRTX | |
|---|---|---|
Market Cap | $1.59B | $63.41M |
Sector | Technology | Health |
52-Week High | $19.66 | $1.49 |
52-Week Low | $7.76 | $0.32 |
Enterprise Value | $1.02B | $161.31M |
Signals from Pluang's Aura AI — not financial advice
C3.ai (AI) trades at $10.22, up 3.65% with a bullish technical signal. The company shows revenue growth to $389M in 2025 but continues significant losses with a -187.95% net income margin. Recent recognition as a leader in AI platforms by Forrester Research (August 10, 2026) provides positive momentum, though cash flow remains negative. Analyst consensus is mixed with 21% buy ratings and a $10.20 price target slightly below current levels.
The outlook remains challenging with persistent losses offset by strong market positioning in enterprise AI. Investment opportunity lies in the company's leadership recognition and sector growth potential, while risks include unsustainable cash burn and competitive pressures. The stock faces near-term resistance at $11 with support at $10.
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
Trailing returns across standard periods
Latest headlines on both assets
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Suite, is a comprehensive application development and runtime environment that is designed to allow customers to rapidly design, develop, and deploy Enterprise AI applications of any type
Read more on AI →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →